A promising cancer treatment strategy called cuproptosis , which uses copper-dependent cell death to eliminate tumor cells, faces a major challenge: many approaches require adding external copper, potentially increasing toxicity beyond the tumor. A new study published in Biomedical Analysis introduces a targeted nanoparticle system that overcomes this limitation by using cancer cells’ own copper resources to activate this form of cell death.
The core of this new system is a biocompatible nanoparticle made from PLGA-PEG , a polymer widely recognized for its safety and degradability. To ensure the nanoparticle reaches its destination, the researchers decorated its surface with a tumor-penetrating peptide called iRGD . This peptide acts like a navigation system, guiding the nanoparticle to bind specifically to tumor cells. The nanoparticle carries a potent payload: N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine ( TPEN ), a chemical agent that chelates, or binds to, metal ions like copper.
The research team meticulously prepared and characterized the final formulation, named TPEN@1%-iPPN . The nanoparticles were found to be uniform in size, measuring approximately 80 nanometers in diameter, an ideal size for accumulating in tumor tissue. Extensive stability tests confirmed that the nanoparticles remained intact under conditions mimicking the human bloodstream, including upon dilution and in the presence of serum proteins. This stability is essential for ensuring the payload reaches the tumor before degrading. The formulation also demonstrated a sustained-release profile, gradually releasing its TPEN cargo over 72 hours, which could help maintain a consistent therapeutic effect within the tumor microenvironment.
The effectiveness of the iRGD targeting peptide was a central focus of the investigation. In laboratory experiments using 4T1 breast cancer cells , the iRGD-modified nanoparticles showed significantly enhanced cellular uptake compared to their non-targeted counterparts. Fluorescence microscopy and flow cytometry analyses confirmed that the targeted nanoparticles were internalized by cancer cells far more efficiently. The researchers determined that a 1% modification with the iRGD peptide provided the optimal balance of targeting efficacy and nanoparticle stability, achieving maximum cellular entry without compromising the formulation.
The ultimate test was whether the nanoparticles could kill cancer cells without harming normal cells. Cytotoxicity assays revealed that the targeted TPEN@1%-iPPN was significantly more lethal to 4T1 breast cancer cells than the non-targeted version. Most importantly, the nanoparticle formulation showed much lower toxicity to normal human endothelial cells (HUVECs) compared to free, untargeted TPEN. This demonstrates a high degree of tumor-selective cytotoxicity , concentrating the drug's lethal effect where it is needed most while protecting healthy tissue. This selectivity is a key advantage that could lead to a wider therapeutic window in future applications.
This preclinical work provides a robust experimental foundation for a new class of cancer nanomedicines that exploit the unique metabolic properties of tumors. By designing a delivery system that is stable, targeted, and capable of activating cuproptosis using endogenous copper, the authors have outlined a promising strategy for developing more precise and effective cancer treatments. This approach avoids the risks of systemic metal administration and offers a new way to think about leveraging a tumor’s internal environment for therapeutic gain.
"Our approach leverages the high copper levels already present in tumors, using a targeted nanoparticle to deliver a chelator that essentially turns the cancer cell's own biology against itself. This strategy of mobilizing endogenous copper offers a promising path to enhance selectivity and reduce the systemic side effects often seen with metal-based cancer therapies. We have provided a solid proof-of-concept at the cellular level, which we hope will inspire further research into cuproptosis-based nanomedicine" said Dr. Ying Chen, corresponding author of this study.
DOI: 10.1016/j.bioana.2026.04.001
Read the full article: https://doi.org/10.1016/j.bioana.2026.04.001
Biomedical Analysis invites submissions for its 2026 Special Issue, “Biosensing and Nanoanalytical Technologies,” scheduled for publication in December 2026. The issue welcomes original research articles and reviews on innovative biosensing strategies, nanoanalytical technologies, functional nanomaterials, optical and electrochemical sensing, signal amplification, imaging, microfluidic and point-of-care platforms, and biomedical applications in disease diagnosis and precision medicine.
The submission deadline is September 30, 2026 . Please refer to the Guide for Authors to prepare your manuscript and select the article type of ": “VSI: Biosensing and Nanoanalytical Technologies" when submitting your manuscript online. Submit your manuscript at: https://www2.cloud.editorialmanager.com/bioana/default2.aspx
Biomedical Analysis is an international, peer-reviewed, open access journal published by Elsevier and KeAi and jointly sponsored by Sun Yat-sen University and the Guangzhou Analysis and Testing Center.
The journal publishes high-quality research in biomedical engineering, bioanalytical chemistry, biochemistry, genetics, biology, biomaterials, medicine, and related interdisciplinary fields, with a particular focus on biomedical testing, sensing technologies, and analytical innovation. Biomedical Analysis is indexed in Scopus, CAS, DOAJ, and EBSCO. Article processing charges (APCs) are currently waived for accepted manuscripts through the end of 2026.
Journal website: https://www.sciencedirect.com/journal/biomedical-analysis .
Biomedical Analysis
Experimental study
Cells
Preparation and evaluation of iRGD-modified PLGA-PEG nanoparticles encapsulating TPEN
14-May-2026
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.